These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28078132)

  • 21. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
    Long GV; Grob JJ; Nathan P; Ribas A; Robert C; Schadendorf D; Lane SR; Mak C; Legenne P; Flaherty KT; Davies MA
    Lancet Oncol; 2016 Dec; 17(12):1743-1754. PubMed ID: 27864013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.
    Rutkowski P; Blank C
    Expert Opin Drug Saf; 2014 Sep; 13(9):1249-58. PubMed ID: 25014231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.
    Richman J; Martin-Liberal J; Diem S; Larkin J
    Expert Opin Pharmacother; 2015 Jun; 16(9):1285-97. PubMed ID: 26001180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
    Robert C; Grob JJ; Stroyakovskiy D; Karaszewska B; Hauschild A; Levchenko E; Chiarion Sileni V; Schachter J; Garbe C; Bondarenko I; Gogas H; Mandalá M; Haanen JBAG; Lebbé C; Mackiewicz A; Rutkowski P; Nathan PD; Ribas A; Davies MA; Flaherty KT; Burgess P; Tan M; Gasal E; Voi M; Schadendorf D; Long GV
    N Engl J Med; 2019 Aug; 381(7):626-636. PubMed ID: 31166680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer.
    Moschetta M; Mak G; Hauser J; Davies C; Uccello M; Arkenau HT
    Exp Hematol Oncol; 2017; 6():1. PubMed ID: 28078189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
    Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA
    BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of BRAF-mutated advanced cutaneous melanoma.
    Trinh VA; You Y; Hwu WJ
    Chin Clin Oncol; 2014 Sep; 3(3):28. PubMed ID: 25841454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
    Joshi M; Rice SJ; Liu X; Miller B; Belani CP
    PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.
    Broman KK; Dossett LA; Sun J; Eroglu Z; Zager JS
    Expert Opin Drug Saf; 2019 May; 18(5):381-392. PubMed ID: 30977681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
    Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
    Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor.
    López de Sá A; de Luna A; Antoñanzas M; García-Barberán V; Moreno-Anton F; García-Sáenz JA
    Front Oncol; 2022; 12():997346. PubMed ID: 36531075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse Event Management in Patients with
    Chalmers A; Cannon L; Akerley W
    Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors.
    Wahid M; Jawed A; Mandal RK; Dar SA; Akhter N; Somvanshi P; Khan F; Lohani M; Areeshi MY; Haque S
    Crit Rev Oncol Hematol; 2018 May; 125():84-88. PubMed ID: 29650281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF and MEK inhibition in melanoma.
    Dossett LA; Kudchadkar RR; Zager JS
    Expert Opin Drug Saf; 2015 Apr; 14(4):559-70. PubMed ID: 25648338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bowel perforation associated with robust response to BRAF/MEK inhibitor therapy for
    Kass SL; Linden AF; Jackson PG; De Brito PA; Atkins MB
    Melanoma Manag; 2015 May; 2(2):115-120. PubMed ID: 30190840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of MEK inhibitors in the treatment of metastatic melanoma.
    Grimaldi AM; Simeone E; Ascierto PA
    Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting BRAF mutations in non-small cell lung cancer.
    O'Leary CG; Andelkovic V; Ladwa R; Pavlakis N; Zhou C; Hirsch F; Richard D; O'Byrne K
    Transl Lung Cancer Res; 2019 Dec; 8(6):1119-1124. PubMed ID: 32010589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
    Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
    Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.